Opioid Use Disorder Clinical Trial
Official title:
Medication-Assisted Treatment for Youth With Substance Use Disorders
The purpose of this open-label pilot study is to determine the tolerability and applicability of outpatient long-acting injectable naltrexone (Vivitrol) treatment in individuals age 16-25 ("older youth") with opioid use disorder. Outpatient treatment will consist of a 7-day outpatient detoxification / naltrexone induction procedure followed by 8-weeks of treatment with Vivitrol.
The rates of opioid use in youth are rising. Long-acting injectable naltrexone (Vivitrol), a
medication that blocks the effects of opioid drugs, has been shown to be effective for
treatment of opioid dependence in adults. Vivitrol is an important option for individuals not
wanting agonist treatment (e.g. buprenorphine, methadone). Vivitrol may be particularly
appealing to youth who have difficulty reaching their opioid use goals with daily oral
medications as it is a monthly injection and therefore eliminates the problem of daily
medication non-adherence. Vivitrol may also be appealing to families as it reduces conflicts
around issues of adherence and thus supports positive parenting. Whereas Vivitrol has been
used clinically in minors, it has not been studied in a prospective outpatient trial.
Starting naltrexone, however, can be challenging in opioid-dependent individuals because
detoxification is required prior to treatment with this medication.There are no standard
outpatient detoxification protocols for opioid-dependent youth. Therefore, more studies are
needed to support broader and approved use of Vivitrol in this population.
The purpose of this open-label pilot study is to determine the tolerability and applicability
of outpatient long-acting injectable naltrexone (Vivitrol) treatment in individuals age 16-25
("older youth") with opioid use disorder. We aim to have 16 older youth complete this trial.
Participants will undergo an outpatient detoxification / induction procedure that has been
honed over the past 13 years of work with this medication by others in our Division and is
currently being used safely in opioid-dependent adults in an ongoing clinical trial. The
detoxification / induction procedure consists of a single day of buprenorphine followed by a
washout day and 4 days of ascending oral naltrexone doses prior to administering a dose of
injectable naltrexone, typically at Day 8. Participants will then receive an additional
Vivitrol injection 4 weeks after the first; they will also receive weekly medication
management therapy with a research psychiatrist. Following the 9 week trial, participants and
are eligible for an additional third injection followed by up to 4 weeks of therapy while
proper follow-up treatment is arranged.
Primary Aim: To determine the tolerability and applicability of outpatient Vivitrol treatment
in individuals aged 16-25 ("older youth") with opioid use disorder as determined by retention
in treatment across the study. Outpatient treatment will consist of a 7-day detoxification /
naltrexone induction procedure followed by 8-weeks of treatment with Vivitrol.
Secondary Aim 1:To determine the tolerability of 7-day outpatient detoxification / naltrexone
induction for older youth as assessed by retention through first administration of Vivitrol.
Secondary Aim 2:To determine the tolerability of initial (4-week) treatment with Vivitrol as
assessed by receipt of the second Vivitrol injection at week 4.
Secondary Aim 3:To determine the safety and tolerability of Vivitrol treatment as assessed
with measures of adverse events.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06021431 -
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
|
N/A | |
Completed |
NCT06266572 -
Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment
|
Phase 1 | |
Recruiting |
NCT05037682 -
Pain and Opioid Management in Older Adults
|
N/A | |
Completed |
NCT06200740 -
Remotely Observed Methadone Evaluation
|
N/A | |
Not yet recruiting |
NCT06441604 -
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
|
Phase 2 | |
Recruiting |
NCT06028126 -
Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial
|
N/A | |
Completed |
NCT02559973 -
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
|
Phase 1 | |
Completed |
NCT02440256 -
Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial
|
N/A | |
Completed |
NCT05587998 -
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
|
Phase 1 | |
Terminated |
NCT04577144 -
An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
|
||
Recruiting |
NCT06001437 -
Following Outcomes Remotely Within Addiction Recovery Domains
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 | |
Completed |
NCT05546229 -
Assessment of Methadone and Buprenorphine in Interstitial Fluid
|
||
Not yet recruiting |
NCT06104280 -
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
|
N/A | |
Not yet recruiting |
NCT06416020 -
Integrating MOUD in African American Community Settings (Better Together)
|
N/A | |
Recruiting |
NCT06206291 -
Cannabidiol for Opioid Addiction
|
Phase 2 | |
Completed |
NCT05552040 -
START NOW in the Treatment of Opioid Addicted Individuals
|
N/A | |
Recruiting |
NCT05459922 -
Adjunctive Bright Light Therapy for Opioid Use Disorder
|
N/A | |
Recruiting |
NCT05343169 -
Community-based Education, Navigation, and Support Intervention for Military Veterans
|
N/A | |
Recruiting |
NCT06081985 -
Efficacy of Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder
|
N/A |